Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HT 61/mupirocin/neomycin - Cadila Pharmaceuticals

Drug Profile

HT 61/mupirocin/neomycin - Cadila Pharmaceuticals

Alternative Names: HT61/mupirocin/neomycin - Cadila Pharmaceuticals; HY 005; HY-005B8a; HY-005B8a topical; Mupirocin/neomycin/HT-61 - Cadila Pharmaceuticals; Neomycin/HT-61/mupirocin - Cadila Pharmaceuticals

Latest Information Update: 12 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cadila Pharmaceuticals
  • Class Aminoglycosides; Antibacterials; Carboxylic acids; Epoxy compounds; Nonanoic acids; Pyrans; Skin disorder therapies; Small molecules
  • Mechanism of Action Cell membrane inhibitors; Cell wall inhibitors; Protein 30S ribosomal subunit inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 12 Dec 2022 HT 61/mupirocin/neomycin is still in phase II development for Methicillin-resistant Staphylococcus aureus infections at Unknown location (Helperby Therapeutics pipeline, December 2022)
  • 15 Jun 2020 Helperby Therapeutics completes a phase II trial in Methicillin-resistant Staphylococcus aureus infections (Topical), before June 2020 (Helperby Therapeutics pipeline, June 2020)
  • 04 Jul 2019 Phase-II clinical trials in Methicillin-resistant Staphylococcus aureus infections (Topical) before July 2019 (Helperby Therapeutics pipeline, July 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top